News
Either Netflix or Paramount buying Warner Bros. Discovery would be an unhappy ending for streaming customers. #Block #Warner #Bros #sale #break #Big #Streaming #give #prices
Nutriband earnings beat by $1.81, revenue fell short of estimates #Nutriband #earnings #beat #revenue #fell #short #estimates
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. When asked what they think about the economy, the British public can sometimes be horribly blunt. In a YouGov survey after November’s Budget, three in four people thought the government was managing the economy badly. … Read more
Veritiv, a major player in specialty packaging distribution and supply chain solutions, has unveiled a groundbreaking addition to its cold chain logistics offerings: TempSafe PalletShield, the industry’s first pre-qualified pallet shipper constructed from curbside-recyclable components. This new product marks a significant advance in sustainable packaging for biopharmaceutical and temperature-sensitive shipments, reflecting growing industry demand for … Read more
March arabica coffee (KCH26) on Friday closed down -6.90 (-1.83%), and January ICE robusta coffee (RMF26) closed down -84 (-2.00%). Coffee prices fell sharply on Friday, with robusta posting a 2.5-month low. The outlook for ample coffee supplies is weighing on prices. Last Thursday, Conab, Brazil’s crop forecasting agency, raised its total Brazil 2025 coffee … Read more
Tilray’s stock, and shares of other cannabis companies, soared after reports provided investors hope that President Trump would move to have marijuana reclassified as a much less dangerous drug than it is now. #Tilrays #stock #takes #hope #cannabis #treated #steroids #heroin
Fighting continues between Thailand, Cambodia after Trump claim of ceasefire #Fighting #continues #Thailand #Cambodia #Trump #claim #ceasefire
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser. #Client #Challenge
Technical Assessment: Bullish in the Intermediate-Term #Technical #Assessment #Bullish #IntermediateTerm
(RTTNews) – Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application (sNDA) for AKEEGA—a dual-action tablet combining niraparib and abiraterone acetate—administered with prednisone. This new treatment is indicated for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). BRCA mutations are associated with more aggressive forms … Read more